Print this page
-
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
- Archana Sharma DO (Rutgers University)
Applicable Disease Sites: Lymphoid Leukemia -
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients.
Protocol: 111708Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.
Protocol: 071807Principal Investigator:
- Howard Hochster M.D (Rutgers University)
Applicable Disease Sites: Colon -
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Any Site -
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones.
Protocol: 111804Principal Investigator:
- Marissa Botwinick MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Leukemia, other
Any Site -
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission.
Protocol: 011813Principal Investigator:
- Matthew Matasar (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Non-Hodgkin's Lymphoma